This article is more than 5 years old. Information may no longer be current.
Cipher gains Canadian commercial rights to Ozenoxacin for treatment of impetigo
Click Here to Manage Email Alerts
Cipher Pharmaceuticals has acquired the Canadian rights to Ozenoxacin, a topical treatment for impetigo in pediatric and adult patients, from Ferrer, according to a press release.
Ferrer, a privately-held Spanish company, completed a phase 3 clinical trial of Ozenoxacin, a non-fluorinated quinolone, in adults and children ages 2 years and older with impetigo in 2013, according to the release.
Ozenoxacin 1% cream applied topically twice daily for 5 days was demonstrated to be superior in both clinical and bacteriological endpoints when compared with placebo. Safety and tolerance of Ozenoxacin also were demonstrated during the trial.
A second phase 3 trial of Ozenoxacin was begun by Ferrer in June 2014 to compare Ozenoxacin 1% cream with placebo treatment in approximately 412 patients ages 2 months and older with non-bullous or bullous impetigo, according to the release. The trial is expected to be completed by the first quarter of 2015.
Ferrer will receive an upfront payment from Cipher and be eligible for development milestones and revenues from sales in Canada, according to the release.
Ozenoxacin will be manufactured by Ferrer, which will deliver the product to Cipher.
Reference: www.cipherpharma.com.